The University of Texas System

Dana-farber-cancer Institute Inc.

Jun Yao

Mien-Chie Hung

Dihua Yu

Xiaoyan Zhou

Ping Li

Wentao Yang

Jun Yang

Christopher L Neal

Raphael E Pollock

Nina T Nguyen

Kornelia Polyak

Min Hu

Noga Qimron

The invention provides a method of analyzing the methylation status of all or part of an entire genome. Moreover, the invention features methods of and reagents for characterizing biological cells containing DNA that is susceptible to methylation. Such methods include methods of diagnosing cancer, e.g., breast cancer.

Gene methylation and expression

Methods of determining prognosis in a subject with a hyperproliferative disease, including determining expression and/or function of 14-3-3 zeta in the subject, are disclosed. Also disclosed are methods of making a pharmaceutical agent that modulates apoptosis, including the steps of obtaining one or more candidate, testing the one or more candidate substances to determine their ability to modulate the expression and/or function of 14-3-3 zeta, selecting a candidate substance determined to modulate the expression and/or function of 14-3-3 zeta, and making a pharmaceutical composition that includes the selected candidate substance. In addition, methods of treating a subject with a hyperproliferative disease, including making a pharmaceutical agent by the methods set forth herein, and administering the pharmaceutical agent to a subject, are disclosed. The hyperproliferative disease can be cancer, such as breast cancer.

14-3-3 Zeta over-expression as a poor prognosis factor, and a therapeutic target in multiple cancer type

14-3-3 zeta over-expression as a poor prognosis factor, and a therapeutic target in multiple cancer types

Growing community of inventors

Chestnut Hill, MA, United States of America

Jun Yao